Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 31, 2024 16:01 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Aptose closes previously announced public offering and private placement
January 26, 2024 08:00 ET | Source: Aptose Biosciences, Inc.

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
December 09, 2023 18:30 ET | Source: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

ASH Oral Presentation: Complete Response Data from the Ongoing APTIVATE Phase 1/2 Study of Tuspetinib (TUS) in R/R AML Patients
November 30, 2023 16:59 ET | Source: Aptose Biosciences, Inc.

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
November 09, 2023 16:00 ET | Source: Aptose Biosciences, Inc.

Aptose Reports Results for the Third Quarter 2023

Aptose Reports Results for the Third Quarter 2023 • TUS/VEN Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path
November 02, 2023 09:00 ET | Source: Aptose Biosciences, Inc.

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Dr. Naval Daver from MD Anderson Cancer Center will present data from Aptose’s AML Drug Candidate Tuspetinib in an Oral Presentation at ASH 2023
October 30, 2023 09:15 ET | Source: Aptose Biosciences, Inc.

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose Presents Latest Available Data on AML Drug Tuspetinib - 48% ORR with TUS/VEN in Heavily Pre-treated R/R AML Patients
October 26, 2023 07:11 ET | Source: Aptose Biosciences, Inc.

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 23, 2023 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Aptose to Hold Clinical Update Webcast and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 16, 2023 07:30 ET | Source: Aptose Biosciences, Inc.

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Aptose to present TUS/VEN AML data at ESH; to hold clinical update webcast on October 30th. TUS appears to re-sensitize Prior-VEN failure patients to VEN.